Anzeige
Mehr »
Login
Dienstag, 01.04.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Kurs-Explosion voraus?: Diese kaum bekannte Aktie bohrt jetzt im Hotspot - und du erfährst es als Erster!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XEH4 | ISIN: FR0011716265 | Ticker-Symbol: 74C
Frankfurt
01.04.25
13:21 Uhr
1,168 Euro
-0,164
-12,31 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
CROSSJECT SA Chart 1 Jahr
5-Tage-Chart
CROSSJECT SA 5-Tage-Chart
RealtimeGeldBriefZeit
1,0541,16222:32

Aktuelle News zur CROSSJECT Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoCROSSJECT reports financial results for 202482Press Release CROSSJECT reports financial results for 2024 Continued satisfactory production of regulatory batches with a view to filing in Q2 2025.Recruitment of Tony Tipton as Chief Operating Officer...
► Artikel lesen
25.03.CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO adrenal insufficiency program72Press Release CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program CROSSJECT enhanced its collaboration with Eton Pharmaceuticals,...
► Artikel lesen
18.03.CROSSJECT achieves key ZEPIZURE manufacturing batch stability milestones1
12.02.Crossject announces the reappointment of Patrick Alexandre and Isabelle Liebschutz as members of new, streamlined Executive Board96Dijon, FRANCE, February 12, 2025 - 0730 (CET) - Crossject (ISIN: FR0011716265; Euronext Growth: ALCJ), a specialty pharma company developing medicines harnessing its unique, award-winning needle-free...
► Artikel lesen
19.12.24Crossject confirms ZEPIZURE supply chain readiness with another successful ISO audit for Quality Management System98Crossject successfully passes another ISO 13485 audit for sites in Dijon and Gray (France)Company is ramping up supply chain to prepare for commercialization in U.S. Dijon, France, December 19, 2024...
► Artikel lesen
11.12.24Crossject announces the pricing of its reserved capital increase and warrants issuance for an aggregate amount of EUR 7.2M2
10.12.24Crossject launches reserved capital increase and warrants issuance for an aggregate amount of at least €7m1
CROSSJECT Aktie jetzt für 0€ handeln
09.12.24Crossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development Agreement1
13.11.24Crossject's ZENEO Auto-Injector's usability further demonstrated in extreme HAZMAT conditions1
22.10.24Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE ahead of filing U.S. Emergency Use Authorization124Product batch announced in July yielded new regulatory stability data. These results will directly support the requested 6-month stability data in the first quarter of 2025Crossject expects to file...
► Artikel lesen
23.09.24Crossject reports financial results and business highlights for the first six months of 2024240Available cash €5.95 million, up from €2.3 million on December 31, 2023Reports stable investments in R&D and consolidation of operating income from BARDACompany on track to successfully file for the...
► Artikel lesen
19.08.24Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE Epilepsy Rescue Treatment247Press Release Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment Experienced executive to lead preparations...
► Artikel lesen
18.07.24Crossject achieves key ZEPIZURE manufacturing milestone171Successful completion of an additional Registration Batch of ZEPIZURE® at new manufacturing siteMilestone complements the satisfying results from previous batches under stability studies, and is...
► Artikel lesen
10.07.24Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO Epinephrine189Key contribution to the acceleration of the development of ZENEO® EpinephrineFinancial support includes mainly grants, as well as subsidized loansFrance 2030 Plan dedicated to supporting French companies...
► Artikel lesen
26.06.24Crossject elaborates on ZEPIZURE potential in light of landmark RAMPART study and its own, recently published, bioequivalence study234Landmark RAMPART study established midazolam intramuscular (IM) injection as a standard of care in the pre-hospital emergency management of epilepsy crises compared to traditional benzodiazepine...
► Artikel lesen
12.06.24Crossject appoints Dan Chiche, MD as Chief Medical Officer North America241Brings extensive experience in drug development in the U.S and internationally and in maximizing value of medical productsReinforces leadership team and expands presence in North AmericaSupports processes...
► Artikel lesen
14.05.24XFRA CAPITAL ADJUSTMENT INFORMATION - 14.05.2024775Das Instrument 3W1 SE0000236382 CONCEJO AB (PUBL) B SK 5 EQUITY wird ex Kapitalmassnahme gehandelt am 14.05.2024 The instrument 3W1 SE0000236382 CONCEJO AB (PUBL) B SK 5 EQUITY is traded ex capital...
► Artikel lesen
25.04.24Crossject reports audited financial results for 2023230Dijon, France April 25, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company developing products for emergency situations harnessing its proprietary needle-free...
► Artikel lesen
08.04.24XFRA 74C: WIEDERAUFNAHME/RESUMPTION273FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
02.04.24Crossject advances in its U.S. Strategy and reports Financial Results for 2023316Increase in visibility in its regulatory and commercialization prospects in the U.S. since latest interactions with the FDAExpectation to receive U.S. Emergency Use Authorization (EUA) for ZEPIZURE®...
► Artikel lesen
Seite:  Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1